Chapter 21 — Scientific Validation & Future Development

The preceding chapters described the scientific foundations, pharmaceutical architecture, Master Formulae and clinical implementation of the SIRIAM Platform.

The present chapter outlines the future scientific development of the platform.

Although the pharmaceutical architecture presented throughout this handbook has been developed through systematic formulation design, magistral preparation, clinical observation and iterative refinement, several aspects remain to be investigated through structured experimental and clinical research.

Accordingly, the SIRIAM Platform should be regarded as an evolving scientific framework rather than a completed therapeutic system.

Future development will focus upon objective validation, optimisation of formulation architecture and multidisciplinary collaboration.

The SIRIAM Platform adopts an evidence-informed development strategy.

Scientific progress follows a continuous cycle:

1. 01Clinical Observation
2. 02Hypothesis Generation
3. 03Formulation Development
4. 04Pilot Evaluation
5. 05Objective Measurement
6. 06Clinical Refinement
7. 07Prospective Validation

Future pharmaceutical investigations may include:

• Formulation stability — accelerated stability, long-term stability, viscosity evolution, pH stability, oxidation profile
• Packaging validation — airless systems, oxygen permeability, light protection, preservative efficacy
• Skin delivery — Future work may investigate: dermal penetration, epidermal retention, follicular transport, release kinetics
• No assumptions regarding enhanced penetration should be made without experimental confirmation.

Future experimental work may investigate:

• regional skin physiology;
• connective tissue mechanics;
• fascial behaviour;
• neurocutaneous interactions;
• autonomic responses;
• regional tissue adaptation.
• The concept of the neurodermal system should remain open to refinement as new evidence emerges.

Surface EMG represents one of the principal objective outcome measures currently incorporated within the SIRIAM Platform.

Future research priorities include:

• intra-observer reliability;
• inter-observer reliability;
• test–retest reproducibility;
• sensitivity to clinical change;
• relationship with patient-reported outcomes;
• comparison with healthy reference populations.
• The objective is to determine whether regional EMG patterns can serve as reproducible biomarkers of neuromuscular adaptation rather than as diagnostic markers.

The Segmental Reflex Screening Test (SRST) constitutes the principal regional assessment method within the platform.

Future validation should investigate:

• inter-rater reliability;
• intra-rater reliability;
• construct validity;
• concurrent validity;
• responsiveness;
• minimal detectable change.
• Future studies should evaluate SRST within well-defined clinical populations using standardised protocols.

Future clinical studies may evaluate:

• symptom evolution;
• functional recovery;
• quality of life;
• regional mobility;
• tissue characteristics;
• longitudinal treatment response.
• Standardised outcome measures should be incorporated wherever possible.

Future investigations may include:

• ultrasound
• shear-wave elastography
• thermography
• MRI (selected indications)
• high-resolution photography
• These techniques may provide complementary objective information regarding regional tissue adaptation.

Potential future biomarkers include:

• inflammatory mediators;
• oxidative stress markers;
• connective tissue biomarkers;
• autonomic measures;
• heart rate variability;
• skin temperature.
• Selection should remain hypothesis-driven and clinically relevant.

Future platform development may incorporate AI-assisted analysis for:

• SRST pattern recognition;
• EMG interpretation;
• treatment-response prediction;
• longitudinal data analysis;
• formulation recommendation support.
• AI systems should function as decision-support tools and not replace clinical judgement.

Future Master Formulae may include:

• additional peripheral nerve systems;
• cranial formulations;
• scar-specific formulations;
• paediatric adaptations;
• specialised sports formulations.
• All future formulations should maintain the pharmaceutical architecture described throughout this handbook.

Suggested progression:

1. 01Phase I — Pharmaceutical validation
2. 02Phase II — Healthy volunteer studies
3. 03Phase III — Pilot clinical studies
4. 04Phase IV — Controlled comparative studies
5. 05Phase V — Multicentre observational research
6. 06Phase VI — International collaboration

Future development should include a structured registry documenting:

• patient demographics;
• regional findings;
• Master Formula selection;
• treatment duration;
• SRST findings;
• EMG measurements;
• patient-reported outcomes;
• adverse events;
• long-term follow-up.
• A prospective registry would facilitate continuous refinement of the platform while supporting future scientific publications.

Several important limitations should be recognised.

The current handbook describes an evidence-informed pharmaceutical platform rather than a fully validated therapeutic system.

Many biological mechanisms proposed throughout the platform remain hypotheses that require experimental confirmation.

Similarly, although numerous individual ingredients possess established scientific evidence, the integrated behaviour of the complete Master Formulae has not yet been evaluated through prospective controlled clinical trials.

Future scientific investigation should therefore prioritise validation of the platform as an integrated system.

The long-term objective of the SIRIAM Platform is not simply the development of topical magistral formulations.

Rather, it seeks to establish a reproducible framework in which pharmaceutical formulation science, regional anatomy, neurodermal biology and objective clinical assessment are integrated into a coherent systems-based approach.

Progress will depend upon collaboration between clinicians, pharmacists, anatomists, neuroscientists, biomedical engineers and academic researchers.

The platform should therefore be regarded as a living scientific programme that evolves through observation, experimentation and critical evaluation.

The SIRIAM Platform presented in this handbook represents the current stage of an ongoing scientific development process. Its pharmaceutical architecture, Master Formulae and clinical workflows have been designed to provide a structured and reproducible framework for regional neurodermal formulation and application. At the same time, the platform recognises that innovation carries the responsibility of rigorous evaluation. Future progress will depend not only on continued formulation refinement but also on transparent scientific investigation, objective measurement and multidisciplinary collaboration. It is through this iterative process that the SIRIAM Platform aims to evolve from an evidence-informed pharmaceutical concept into a scientifically validated clinical framework.